Danaher Corporation (LON:0R2B)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 106.54B |
| Revenue (ttm) | 17.51B |
| Net Income (ttm) | 2.49B |
| Shares Out | n/a |
| EPS (ttm) | 3.44 |
| PE Ratio | 42.81 |
| Forward PE | 24.00 |
| Dividend | 0.90 (0.45%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 677 |
| Average Volume | 2,502 |
| Open | 195.00 |
| Previous Close | 199.35 |
| Day's Range | 192.48 - 196.13 |
| 52-Week Range | 171.02 - 283.88 |
| Beta | 0.80 |
| RSI | 49.99 |
| Earnings Date | Jul 22, 2025 |
About United States Steel
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manuf... [Read more]
Financial Performance
In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.
Financial StatementsNews
Investors decided the good outweighs the bad with Danaher, says Jim Cramer
'Mad Money' host Jim Cramer talks how to play Danaher after earnings.
Investors decided the good outweighs the bad with Danaher, says Jim Cramer
'Mad Money' host Jim Cramer talks how to play Danaher after earnings.
Danaher Q2 2025 Update
Danaher Stock: Attractively Valued And Poised For Growth Acceleration
Danaher Corporation thrives on bioprocessing demand & diagnostics resilience. Click for why, with solid execution & 80% recurring revenue, DHR offers upside.
Danaher Raises 2025 Earnings Outlook
Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline
Danaher Corp (NYSE: DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the consensus of $5.84 billion . The life science giant reported adjusted earn...
Danaher raises full-year EPS guidance to $7.70-$7.80 amid robust bioprocessing growth and portfolio resilience
Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript
Danaher (DHR) Q2 2025 Earnings Call Transcript
Cramer's Stop Trading: Danaher
Jim Cramer breaks down why he's keeping an eye on shares of Danaher.
Cramer's Stop Trading: Danaher
Jim Cramer breaks down why he's keeping an eye on shares of Danaher.
Danaher slips despite Q2 beat as Life Sciences unit underperforms
Danaher lifts annual profit view on strength in diagnostics, names new CFO
Life sciences firm Danaher raised its annual profit forecast on Tuesday, banking on resilient demand for its diagnostic testing tools and services.
Danaher names new finance chief
Earnings Snapshot: Danaher surpasses Q2 estimates; raises FY25 Adj. EPS outlook
Danaher Announces Transition Plan for Chief Financial Officer
WASHINGTON , July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Matthew Gugino, currently Group Chief Financi...
Danaher Non-GAAP EPS of $1.80 beats by $0.16, revenue of $5.9B beats by $60M
Danaher Reports Second Quarter 2025 Results
WASHINGTON , July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 27, 2025. Key Second Quarter 2025 Results Net earnings wer...
Danaher Q2 2025 Earnings Preview
45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs
I analyze Barron's Mid-Year 2025 Roundtable Pro Picks using the yield-based 'dogcatcher' method to identify high-yield, safer dividend stocks. AT&T, Tegna, and Pitney Bowes stand out as 'safer' divide...
3-Stock Lunch: Danaher, Progressive, Alphabet
CNBC's "Power Lunch" team is joined by Mike Bailey, director of research at FBB Capital Partners, to discuss what three stocks he is watching.
Illumina downgraded at Scotiabank on outlook; Danaher, Thermo Fisher upgraded
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Evercore ...
Our bottom 5 stocks for the first half of 2025 and why we still own them
This is what it will take to for a turnaround in shares of Salesforce, Apple, Bristol Myers, DuPont and Danaher.